Cargando…
Comparing treatment outcomes of concurrent chemoradiotherapy with or without nimotuzumab in patients with locoregionally advanced nasopharyngeal carcinoma
Purpose: The benefits of additional use of nimotuzumab (NTZ) in the treatment of locoregionally advanced nasopharyngeal carcinoma (LA-NPC) is largely unclear. We aim to compare LA-NPC treatment outcomes in patients that received CCRT with nimotuzumab (NTZ) to patients that received CCRT only. Materi...
Autores principales: | Yao, Ji-Jin, Zhang, Lu-Lu, Gao, Tian-Sheng, Peng, Ying-Lin, Lawrence, Wayne R., Zhang, Wang-Jian, Zhang, Fan, Zhou, Guan-Qun, Wang, Si-Yang, Sun, Ying |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6301798/ https://www.ncbi.nlm.nih.gov/pubmed/30081714 http://dx.doi.org/10.1080/15384047.2018.1491501 |
Ejemplares similares
-
Efficacy and safety of nimotuzumab with neoadjuvant chemotherapy followed by concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma
por: Wang, Fangzheng, et al.
Publicado: (2017) -
Nimotuzumab combined with concurrent chemoradiotherapy benefits patients with advanced nasopharyngeal carcinoma
por: Li, Zhanzhan, et al.
Publicado: (2017) -
Induction chemotherapy plus nimotuzumab followed by concurrent chemoradiotherapy for advanced nasopharyngeal carcinoma
por: Song, Xinmao, et al.
Publicado: (2019) -
Nimotuzumab combined with concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma: a retrospective analysis
por: Liu, Zhi-gang, et al.
Publicado: (2016) -
Identification of surrogate endpoints in patients with locoregionally advanced nasopharyngeal carcinoma receiving neoadjuvant chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone
por: Chen, Yu-Pei, et al.
Publicado: (2015)